Michael Castagna

“I'll start with some opening remarks, walk you through some business updates.”

“For those of you who don't know Mankind, we've been around since 1991. Most dry powder companies don't survive 35 years with the good fortunes that we've had. We've gotten two FDA-approved products, one inhaled insulin, which got approved in 2014 and just last Friday got approved for pediatrics.”

“Here is today's agenda, and I will start with some opening remarks. In the first quarter, we continued to execute our strategy to evolve MannKind Corporation into a diversified company positioned to deliver sustained long-term growth.”

“Here is today's agenda, and I'll start with some opening remarks. I want to start by taking a step back and putting our relationship with United Therapeutics into context.”

“We delivered a record revenue quarter of $82 million. We also strengthened our portfolio with the acquisition of scPharmaceuticals. On the pipeline side, Afrezza supplemental BLA was accepted for review with a PDUFA date of Q2 2026.”